Nasus Pharma (NSRX) Other Non-Current Liabilities (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Other Non-Current Liabilities came in at $2.6 million in Q2 2025, up 42.23% on a QoQ basis from $1.8 million in Q4 2024.
Nasus Pharma (NSRX) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Other Non-Current Liabilities data on file, last reported at $2.6 million in Q2 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $2.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.6 million (changed N/A YoY) and the FY2024 annual result came in at $1.8 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $2.6 million in Q2 2025, from $1.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.6 million in Q2 2025 to a low of $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Nasus Pharma | 30.76 Mn | 30.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.56 Mn |
| Dec 31, 2024 | 1.80 Mn |